MNMD实时信号 | 通过Getagraph.com最大化利润

购买 107867 min ago

@ $4.45

发出时间: 15 Feb 2024 @ 01:00

回报率: 101.12%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: -4.40 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:47):

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology...

Stats
今日成交量	369 969
平均成交量	2.29M
市值	630.98M
EPS	$0 ( 2024-02-28 )
下一个收益日期	( $-0.660 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.67
ATR14	$0.0380 (0.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-25	Greenway Schond L.	Sell	5 560	Common Shares
2024-03-25	Karlin Dan	Sell	6 578	Common Shares
2024-03-25	Barrow Robert	Sell	16 519	Common Shares
2024-02-27	Wernli Miri Halperin	Buy	125 000	Stock Option (Right to Buy)
2024-02-27	Greenway Schond L.	Buy	150 000	Stock Option (Right to Buy)

INSIDER POWER
89.87
Last 96 transactions
Buy: 11 612 599 \| Sell: 348 471

音量相关性

長: 0.34 (neutral)

短: 0.99 (very strong)

Signal:(73.708) Expect same movement, but be aware

Mind Medicine (MindMed) 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Mind Medicine (MindMed) 相关性 - 货币/商品

-0.02
( neutral )

-0.06
( neutral )

0.00
( neutral )

-0.41
( neutral )

0.75
( moderate )

-0.21
( neutral )

Mind Medicine (MindMed) 财务报表

Annual	2023
营收:	$0
毛利润:	$-3.16M (0.00 %)
EPS:	$-2.44

FY	2023
营收:	$0
毛利润:	$-3.16M (0.00 %)
EPS:	$-2.44

FY	2022
营收:	$0
毛利润:	$-3.22M (0.00 %)
EPS:	$-1.530

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-3.14

Financial Reports:

No articles found.

Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

实时更新： Mind Medicine (MindMed) [MNMD]

Upcoming Earnings Alert